In tamoxifen resistant ER-positive breast cancer cell line, aspirin might also inhibit the upstream regulators of c-myc and cyclinD1 proteins, such as the mTOR signaling [36, 48], wnt/β-catenin [49, 50] and NF-κB pathways [51, 52]. This evidence concerns the gene ESR1 and breast cancer.